Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded up 4% during mid-day trading on Monday . The company traded as high as $9.24 and last traded at $9.20, with a volume of 858,876 shares trading hands. The stock had previously closed at $8.85.

A number of analysts have recently issued reports on the stock. Robert W. Baird reissued an “outperform” rating and set a $10.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, June 6th. Leerink Swann reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, June 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, April 26th. Jefferies Group reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Tuesday, August 9th. Finally, Chardan Capital assumed coverage on shares of Achillion Pharmaceuticals in a research note on Thursday, July 14th. They set a “sell” rating and a $4.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $9.63.

The stock has a market capitalization of $1.28 billion and a price-to-earnings ratio of 191.22. The company’s 50 day moving average is $8.73 and its 200-day moving average is $8.20.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same period last year, the company earned ($0.25) earnings per share. On average, equities research analysts predict that Achillion Pharmaceuticals Inc. will post ($0.63) EPS for the current year.

An institutional investor recently raised its position in Achillion Pharmaceuticals stock. Rhumbline Advisers increased its position in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 14.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 117,525 shares of the biopharmaceutical company’s stock after buying an additional 14,425 shares during the period. Rhumbline Advisers owned 0.09% of Achillion Pharmaceuticals worth $1,268,000 as of its most recent filing with the SEC.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.